Brown, Lisle/Cummings’s Royalty Pharma RPRX Stock Holding History

Brown, Lisle/Cummings’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.4K	Buy	+217	New	+$9.5K	﹤0.01%	569

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Brown, Lisle/Cummings's RPRX Position: Q1 2026 in Review

Brown, Lisle/Cummings opened a new position in Royalty Pharma (RPRX) in Q1 2026: 217 shares worth $10.4K. The stake represents ﹤0.01% of the portfolio and ranks #569 among its holdings.

590 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Brown, Lisle/Cummings held 217 shares of Royalty Pharma worth $10.4K as of Q1 2026.
Royalty Pharma was a new Brown, Lisle/Cummings position in Q1 2026.
Royalty Pharma made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #569 holding.
590 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.